Business
Pharma Equity Group – Strategic update and adjustment of expectations
Pharma Equity Group – Strategic update and adjustment of expectations Copenhagen, 29 December 2025 Company Announcement no. 16 Pharma Equity Group A/S (“PEG” or the “Company”) hereby provides a strategic update regarding the Company’s revenue expectations, the development of the pipeline projects RNX-051 and RNX-011, and the overall commercialisation strategy. Adjustment of previously communicated expectations The Company notes that the revenue and earnings expectations for the current financial
About this update from Pharma Equity Group A/s Class A
[{"type":"image","alt":"Pharma Equity Group A/S","displaySize":"","headline":null,"caption":"Pharma Equity Group A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PTz7GpCf_hKeFTaw0Xo7Fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c","width":300,"height":34}},"lazy":false},{"type":"text","content":"Pharma Equity Group – Strategic update and adjustment of expectations","length":69,"tagName":"p"},{"type":"text","content":"Copenhagen, 29 December 2025","length":28,"tagName":"p"},{"type":"text","content":"Company Announcement no. 16","length":27,"tagName":"p"},{"type":"text","content":"Pharma Equity Group A/S (“PEG” or the “Company”) hereby provides a strategic update regarding the Company’s revenue expectations, the development of the pipeline projects RNX-051 and RNX-011, and the overall commercialisation strategy.","length":235,"tagName":"p"},{"type":"text","content":"Adjustment of previously communicated expectations","length":50,"tagName":"p"},{"type":"text","content":"The Company notes that the revenue and earnings expectations for the current financial year, as previously communicated in the Annual Report for 2024 and the Interim Report for H1 2025, are no longer considered accurate.","length":220,"tagName":"p"},{"type":"text","content":"In this context, the Company previously communicated an expected revenue of approximately DKK 11 million for the financial year 2025. The Company now expects no revenue for the financial year 2025.","length":197,"tagName":"p"},{"type":"text","content":"Furthermore, the Company previously communicated an expected pre-tax loss in the range of DKK 4 to 7 million for the financial year 2025. The Company now expects a pre-tax loss in the range of DKK 18 to 20 million for the Group for the financial year 2025.","length":256,"tagName":"p"},{"type":"text","content":"The adjustment does not reflect any deterioration in the quality or potential of the underlying assets. Rather, it is the result of a deliberate strategic decision to prioritise long-term value creation over entering into short-term, suboptimal agreements.","length":256,"tagName":"p"},{"type":"text","conten...